Loading...

CLSD CLEARSIDE BIOMEDICAL INC Investments/Divestments 8-K Filing

CLRS

CLSD

CLEARSIDE BIOMEDICAL INC

(CLSD)

2023 8-K

Show Summary

Summary

Delisting Notice

Management Changes

Financial Statements

Financial Results

Nasdaq Compliance Notice

Corporate Presentation

Financial Results

Positive Trial Results

Financial Results

Webinar Presentation

Annual Meeting of Stockholders

Appointment of Director

Registered Direct Offering

Amendment to License Agreement

Agreement Amendment

License Agreement with BioC...

Earnings Reports

Equity Offering

Clinical Trial Announcement

Earnings Reports

Resignation and Appointment

Resignation of Officer

Results of OASIS Extension ...

External Links:

Clearside Biomedical, Inc. entered into a license agreement with BioCryst Pharmaceuticals, granting BioCryst an exclusive license for the delivery of avoralstat for the treatment of diabetic macular edema, with potential milestone payments and royalties.

AI Assistant

CLEARSIDE BIOMEDICAL INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.